1. Home
  2. DSS vs BLRX Comparison

DSS vs BLRX Comparison

Compare DSS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DSS Inc.

DSS

DSS Inc.

HOLD

Current Price

$0.95

Market Cap

9.2M

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.67

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSS
BLRX
Founded
1984
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
12.6M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
DSS
BLRX
Price
$0.95
$2.67
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
24.6K
9.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
42.45
N/A
EPS
N/A
N/A
Revenue
$2,085,000.00
N/A
Revenue This Year
$14.93
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$2.30
52 Week High
$1.90
$7.77

Technical Indicators

Market Signals
Indicator
DSS
BLRX
Relative Strength Index (RSI) 50.97 41.70
Support Level $0.91 $2.66
Resistance Level $0.97 $3.11
Average True Range (ATR) 0.05 0.18
MACD 0.01 -0.01
Stochastic Oscillator 40.76 23.92

Price Performance

Historical Comparison
DSS
BLRX

About DSS DSS Inc.

DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: